Michael David Alpert
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$18.9MFederal grants as PI27 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
27 awards · $18.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 24, 2026 | NIH | SBIR Phase II Non-viral gene therapy to treat and prevent atherosclerosis | $300K | EMMUNE INC |
| Jul 24, 2026 | NIH | SBIR Phase II PK, tolerability, and toxicology studies for eCD4-Ig as a long-acting recombinant protein therapeutic | $299K | EMMUNE INC |
| Sep 23, 2025 | NIH | SBIR Phase II Process development for manufacturing eCD4-Ig | $1000K | EMMUNE INC |
| Aug 5, 2025 | NIH | SBIR Phase II SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $1.0M | EMMUNE INC |
| May 9, 2025 | NIH | SBIR Phase I IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic | $300K | EMMUNE INC |
| Jul 18, 2024 | NIH | SBIR Phase II SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $1.0M | EMMUNE INC |
| Feb 8, 2024 | NIH | SBIR Phase II Glycoengineering eCD4-Ig | $975K | EMMUNE INC |
| Aug 17, 2023 | NIH | SBIR Phase II SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $1.0M | EMMUNE INC |
| Feb 16, 2023 | NIH | SBIR Phase II Engineering AAV capsids for enhanced transduction of skeletal muscle | $1.0M | EMMUNE INC |
| Feb 10, 2023 | NIH | SBIR Phase II Glycoengineering eCD4-Ig | $1.0M | EMMUNE INC |
| Dec 22, 2022 | NIH | SBIR Phase II Process development for manufacturing eCD4-Ig | $300K | EMMUNE INC |
| Aug 8, 2022 | NIH | SBIR Phase II SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $300K | EMMUNE INC |
| Apr 15, 2022 | NIH | SBIR Phase II Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | $907K | EMMUNE INC |
| Mar 9, 2022 | NIH | SBIR Phase II Glycoengineering eCD4-Ig | $975K | EMMUNE INC |
| Feb 17, 2022 | NIH | SBIR Phase II Engineering AAV capsids for enhanced transduction of skeletal muscle | $1.0M | EMMUNE INC |
| Jul 13, 2021 | NIH | SBIR Phase II Glycoengineering eCD4-Ig | $300K | EMMUNE INC |
| Apr 16, 2021 | NIH | SBIR Phase II Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | $871K | EMMUNE INC |
| Aug 18, 2020 | NIH | SBIR Phase II Engineering AAV capsids for enhanced transduction of skeletal muscle | $293K | EMMUNE INC |
| Jul 20, 2020 | NIH | SBIR Phase II Development of AAV vectors for long-term expression of eCD4-Ig | $999K | EMMUNE INC |
| Jul 17, 2019 | NIH | SBIR Phase II Development of AAV vectors for long-term expression of eCD4-Ig | $1000K | EMMUNE INC |
| Aug 27, 2018 | NIH | SBIR Phase II Development of AAV vectors for long-term expression of eCD4-Ig | $1000K | EMMUNE INC |
| Jan 30, 2018 | NIH | SBIR Phase II WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION? | $999K | EMMUNE INC |
| Jan 5, 2018 | NIH | SBIR Phase I Cpf1-mediated inactivation of an AAV transgene | $300K | EMMUNE INC |
| Jul 25, 2017 | NIH | SBIR Phase II Development of AAV vectors for long-term expression of eCD4-Ig | $299K | EMMUNE INC |
| Feb 9, 2017 | NIH | SBIR Phase II WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION? | $937K | EMMUNE INC |
| Jun 10, 2016 | NIH | SBIR Phase II WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION? | $298K | EMMUNE INC |
| Jun 14, 2015 | NIH | SBIR Phase I Development of a synthetic antibody based on the HIV receptor and co-receptor that is optimized for highly efficient killing of HIV-infected cells by ADCC | $224K | EMMUNE INC |
Peer ranks
Federal funding#8
Awards as PI#9
Patents#273
Companies
- EMMUNE INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.